FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions
Date Added:
December 10, 2018
Journal/Publication:
FDA News Release
Publisher:
U.S. Food and Drug Administration
Publication Date:
July 10, 2018
Type:
Notifications and Opportunities
Format:
Web Page
Abstract
The U.S. Food and Drug Administration today is requiring safety labeling changes for a class of antibiotics called fluoroquinolones to strengthen the warnings about the risks of mental health side effects and serious blood sugar disturbances, and make these warnings more consistent across the labeling for all fluoroquinolones taken by mouth or given by injection.
Text Availability
Free full text
RPR Commentary
The more we learn about the potential adverse effects of fluoroquinolones, the more we should try to avoid their use, particularly for self-limited conditions like sinusitis and bronchitis.